UC Davis CTSC Clinical Research Center Supports 2 COVID-19 Studies

COVID Clinical Research

The UC Davis CTSC Clinical Research Center is supporting two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. The studies are evaluating the safety and effectiveness of two drugs — the investigational antiviral remdesivir, and sarilumab, a drug that blocks the body’s acute inflammatory response. 

“We have a critical need to confirm safe and effective treatments for COVID-19,” said Allison Brashear, dean of the UC Davis School of Medicine. “Although some patients with severe infection have received remdesivir, we do not have solid data to indicate it can improve clinical outcomes for everyone. The nation’s schools of medicine have the expertise and resources to advance knowledge about the infection to help guide the clinical care of patients worldwide.”

There are no specific therapeutic agents approved by the Food and Drug Administration (FDA) to treat people with COVID-19. The infection can cause mild to severe respiratory illness. Symptoms can include fever, cough and shortness of breath. Current clinical care of hospitalized patients include supplemental oxygen therapy, antibiotics, influenza antiviral drugs and intensive care as needed.

Publishing CTSA Program Hub’s Name